Chemopreventive actions by enterolactone and 13 VIOXX®-related lactone derivatives in H295R human adrenocortical carcinoma cells

Toxicology Letters

Volumn 192, Issue 3, 2010, Pages 271-277

  van Duursen, Majorie B M ^a   Nijmeijer, Sandra M ^a   Ruchirawat, Somsak ^b   van den Berg, Martin ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Toxicology and Management of Chemicals   (Thailand)

Author keywords

Chemoprevention; CYP17; H295R; Lactone derivatives; Sex steroidogenesis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CRI 1; CRI 10; CRI 11; CRI 12; CRI 13; CRI 2; CRI 3; CRI 4; CRI 5; CRI 6; CRI 7; CRI 8; CRI 9; CYTOCHROME P450 17; ENTEROLACTONE; LACTONE DERIVATIVE; MESSENGER RNA; ROFECOXIB; TUBULIN; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION;

4-BUTYROLACTONE; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; ENZYME INDUCTION; FLAVONOIDS; GENE EXPRESSION; HUMANS; LACTONES; LIGNANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS, HORMONE-DEPENDENT; PHYTOESTROGENS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 75349083872     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.11.001     Document Type: Article

References (68)

1. Adams J.B., and Li K. Biosynthesis of 17beta-oestradiol in human breast carcinoma tissue and a novel method for its characterization. Br. J. Cancer 31 (1975) 429-433
2. Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol. 3 (2002) 364-373
3. Adlercreutz H., Fotsis T., Bannwart C., Wahala K., Makela T., Brunow G., and Hase T. Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J. Steroid Biochem. 25 (1986) 791-797
4. Agarwal V.R., Bulun S.E., Leitch M., Rohrich R., and Simpson E.R. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab. 81 (1996) 3843-3849
5. Biason-Lauber A., Kempken B., Werder E., Forest M.G., Einaudi S., Ranke M.B., Matsuo N., Brunelli V., Schonle E.J., and Zachmann M. 17alpha-hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation. J. Clin. Endocrinol. Metab. 85 (2000) 1226-1231
6. Bingham S.A., Atkinson C., Liggins J., Bluck L., and Coward A. Phyto-oestrogens: where are we now?. Br. J. Nutr. 79 (1998) 393-406
7. Borriello S.P., Setchell K.D., Axelson M., and Lawson A.M. Production and metabolism of lignans by the human faecal flora. J. Appl. Bacteriol. 58 (1985) 37-43
8. Brooks J.D., and Thompson L.U. Mammalian lignans and genistein decrease the activities of aromatase and 17β-hydroxysteroid dehydrogenase in MCF-7 cells. J. Steroid Biochem. Mol. Biol. 94 (2005) 461-467
9. Bruno R.D., and Njar V.C.O. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg. Med. Chem. 15 (2007) 5047-5060
10. Canton R.F., Sanderson J.T., Nijmeijer S., Bergman A., Letcher R.J., and van den Berg M. In vitro effects of brominated flame retardants and metabolites on CYP17 catalytic activity: a novel mechanism of action?. Toxicol. Appl. Pharmacol. 216 (2006) 274-281
11. Carey A.H., Waterworth D., Patel K., White D., Little J., Novelli P., Franks S., and Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet. 3 (1994) 1873-1876
12. Castagnetta L.A., Granata O.M., Cocciadiferro L., Saetta A., Polito L., Bronte G., Rizzo S., Campisi I., Agostara B., and Carruba G. Sex steroids, carcinogenesis, and cancer progression. Ann. N.Y. Acad. Sci. 1028 (2004) 233-246
13. Chakraborty A., Murthy N.S., Chintamani C., Bhatnagar D., Mohil R.S., Sharma P.C., and Saxena S. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J. Hum. Genet. 52 (2007) 159-165
14. Chung B.C., Picado-Leonard J., Haniu M., Bienkowski M., Hall P.F., Shively J.E., and Miller W.L. Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 407-411
15. D'Amato R.J., Lin C.M., Flynn E., Folkman J., and Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3964-3968
16. Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89 (1986) 271-277
17. Dixon R.A. Phytoestrogens. Annu. Rev. Plant Biol. 55 (2004) 225-261
18. Dorai T., and Aggarwal B.B. Role of chemopreventive agents in cancer therapy. Cancer Lett. 215 (2004) 129-140
19. Evans B.A., Griffiths K., and Morton M.S. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J. Endocrinol. 147 (1995) 295-302
20. Feigelson H.S., Shames L.S., Pike M.C., Coetzee G.A., Stanczyk F.Z., and Henderson B.E. Cytochrome P450c17{alpha} gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 58 (1998) 585-587
21. Fluck C.E., Miller W.L., and Auchus R.J. The 17, 20-lyase activity of cytochrome p450c17 from human fetal testis favors the delta5 steroidogenic pathway. J. Clin. Endocrinol. Metab. 88 (2003) 3762-3766
22. Glade M.J. Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutrition 15 (1999) 523-526
23. Gower D.B. Modifiers of steroid hormone metabolism: a review of their chemistry, biochemistry and clinical applications. J. Steroid Biochem. 5 (1974) 501-523
24. Gracia T., Hilscherova K., Jones P.D., Newsted J.L., Zhang X., Hecker M., Higley E.B., Sanderson J.T., Yu R.M.K., Wu R.S.S., and Giesy J.P. The H295R system for evaluation of endocrine-disrupting effects. Ecotoxicol. Environ. Saf. 65 (2006) 293-305
25. Graham, D.J., Campen, D., Cheetam, C., Hui, R., Spence, M., Levy, G., Shoor, S., Ray, W., 2004. Risk of acute myocardial infarction and sudden cardiac death in patients treated with COX-2 selective and non-selective NSAIDs. FDA Public Health Advisory Report, September 30, 2004.
26. Henningson M., Johansson U., Borg A., Olsson H., and Jernström H. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women. Mol. Hum. Reprod. 13 (2007) 231-236
27. Kagimoto M., Winter J.S., Kagimoto K., Simpson E.R., and Waterman M.R. Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. Mol. Endocrinol. 2 (1988) 564-570
28. Keinan-Boker L., van Der Schouw Y.T., Grobbee D.E., and Peeters P.H. Dietary phytoestrogens and breast cancer risk. Am. J. Clin. Nutr. 79 (2004) 282-288
29. Kempna P., Hofer G., Mullis P.E., and Fluck C.E. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol. Pharmacol. 71 (2007) 787-798
30. Kirk C., Harris R., Wood D., Waring R., and Hughes P. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens?. Biochem. Soc. Trans. 29 (2001) 209-216
31. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., and Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 (1997) 863-870
32. Kundu J.K., and Surh Y.-J. Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. Cancer Lett. 269 (2008) 243-261
33. Lee-Robichaud P., Wright J.N., Akhtar M.E., and Akhtar M. Modulation of the activity of human 17 alpha-hydroxylase-17,20-lyase (CYP17) by cytochrome b5: endocrinological and mechanistic implications. Biochem. J. 308 Pt 3 (1995) 901-908
34. Limer J.L., and Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res. 6 (2004) 119-127
35. Linseisen J., Piller R., Hermann S., and Chang-Claude J. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int. J. Cancer 110 (2004) 284-290
36. Little J., and Simard J. CYP17 and breast cancer: no overall effect, but what about interactions?. Breast Cancer Res. 7 (2005) 238-242
37. Liu R.H. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr. 134 (2004) 3479S-3485S
38. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
39. Magee P.J., and Rowland I.R. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br. J. Nutr. 91 (2004) 513-531
40. Makela T.H., Wahala K.T., and Hase T.A. Synthesis of enterolactone and enterodiol precursors as potential inhibitors of human estrogen synthetase (aromatase). Steroids 65 (2000) 437-441
41. Mazur W., and Adlercreutz H. Naturally occurring oestrogens in food. Pure Appl. Chem. 70 (1998) 1759-1776
42. McCann S.E., Moysich K.B., Freudenheim J.L., Ambrosone C.B., and Shields P.G. The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. J. Nutr. 132 (2002) 3036-3041
43. Meloche S., and Pouyssegur J. The ERK1//2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26 (2007) 3227-3239
44. Miyoshi Y., Ando A., Ooka M., Shiba E., Taguchi T., Tamaki Y., and Noguchi S. Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue. Cancer Lett. 195 (2003) 81-86
45. Murillo G., and Mehta R.G. Cruciferous vegetables and cancer prevention. Nutr. Cancer 41 (2001) 17-28
46. Olsen A., Knudsen K.E.B., Thomsen B.L., Loft S., Stripp C., Overvad K., Moller S., and Tjonneland A. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 2084-2089
47. Pattyn F., Robbrecht P., De Paepe A., Speleman F., and Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res. 34 (2006) D684-688
48. Payne A.H., and Hales D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev. 25 (2004) 947-970
49. Pearce S.T., and Jordan V.C. The biological role of estrogen receptors alpha and beta in cancer. Crit. Rev. Oncol. Hematol. 50 (2004) 3-22
50. Peeters P.H., Keinan-Boker L., van der Schouw Y.T., and Grobbee D.E. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res. Treat. 77 (2003) 171-183
51. Piller R., Verla-Tebit E., Wang-Gohrke S., Linseisen J., and Chang-Claude J. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J. Nutr. 136 (2006) 1596-1603
52. Puche C., José M., Cabero A., and Meseguer A. Expression and enzymatic activity of the P450c17 gene in human adipose tissue. Eur. J. Endocrinol. 146 (2002) 223-229
53. Quan H., Xu Y., and Lou L. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int. J. Cancer 122 (2008) 1730-1737
54. Roux P.P., and Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68 (2004) 320-344
55. Sanderson J.T. The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals. Toxicol. Sci. 94 (2006) 3-21
56. Sanderson J.T., and van den Berg M. Interaction of xenobiotics with steroid hormone metabolic pathways. Pure Appl. Chem. 75 (2003)
57. Sanderson T., Renaud M., Scholten D., Nijmeijer S., van den Berg M., Cowell S., Guns E., Nelson C., Mutarapat T., and Ruchirawat S. Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells. Eur. J. Pharmacol. 593 (2008) 92-98
58. Sangjun S., de Jong E., Nijmeijer S., Mutarapat T., Ruchirawat S., van den Berg M., and van Duursen M.B. Induction of cell cycle arrest in human MCF-7 breast cancer cells by cis-stilbene derivatives related to VIOXX. Toxicol. Lett. 186 (2009) 115-122
59. Sekharam M., Trotti A., Cunnick J.M., and Wu J. Suppression of fibroblast cell cycle progression in G1 phase by N-acetylcysteine. Toxicol. Appl. Pharmacol. 149 (1998) 210-216
60. Sewer M.B., and Waterman M.R. cAMP-dependent protein kinase enhances CYP17 transcription via MKP-1 activation in H295R human adrenocortical cells. J. Biol. Chem. 278 (2003) 8106-8111
61. Syed D.N., Suh Y., Afaq F., and Mukhtar H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett. 265 (2008) 167-176
62. Tham D.M., Gardner C.D., and Haskell W.L. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J. Clin. Endocrinol. Metab. 83 (1998) 2223-2235
63. Tsao A.S., Kim E.S., and Hong W.K. Chemoprevention of cancer. CA Cancer J. Clin. 54 (2004) 150-180
64. van Gils C.H., Peeters P.H., Bueno-de-Mesquita H.B., Boshuizen H.C., Lahmann P.H., Clavel-Chapelon F., Thiebaut A., Kesse E., Sieri S., Palli D., Tumino R., Panico S., Vineis P., Gonzalez C.A., Ardanaz E., Sanchez M.J., Amiano P., Navarro C., Quiros J.R., Key T.J., Allen N., Khaw K.T., Bingham S.A., Psaltopoulou T., Koliva M., Trichopoulou A., Nagel G., Linseisen J., Boeing H., Berglund G., Wirfalt E., Hallmans G., Lenner P., Overvad K., Tjonneland A., Olsen A., Lund E., Engeset D., Alsaker E., Norat T., Kaaks R., Slimani N., and Riboli E. Consumption of vegetables and fruits and risk of breast cancer. JAMA 293 (2005) 183-193
65. Verla-Tebit E., Wang-Gohrke S., and Chang-Claude J. CYP17 5′-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Breast Cancer Res. 7 (2005)
66. Wood J.A., Hadfield J.A., Pettit G.R., Fox B.W., and Mcgown A.T. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer 71 (1995) 705-711
67. Zhang L.H., Rodriguez H., Ohno S., and Miller W.L. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10619-10623
68. Zhang Q., Peng Y., Wang X.I., Keenan S.M., Arora S., and Welsh W.J. Highly potent triazole-based tubulin polymerization inhibitors. J. Med. Chem. 50 (2007) 749-754